OncoMatch/Clinical Trials/NCT06486142
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
Is NCT06486142 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Afatinib/Dacomitinib and Osimertinib for non-small cell lung cancer.
Treatment: Afatinib/Dacomitinib · Osimertinib — The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment. Life quality, adverse effects and tumor response will be evaluated and analyses of obtained blood and tumor samples will be performed to identify molecular profiles and biomarkers that can be used for treatment decisions.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR mutation predictive of sensitivity to egfr tki
Disease stage
Required: Stage III, IV
Prior therapy
Lab requirements
Kidney function
Renal function incompatible with study drug according to investigator
Liver function
Severe hepatic impairment incompatible with study drug according to investigator
Severe hepatic impairment/renal function incompatible with study drug according to investigator. Abnormal findings of blood chemistry not compatible with the study drug according to investigator.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify